Yescarta® (axicabtagene ciloleucel) – New indication
March 5, 2021 - Kite, a Gilead Company, announced the FDA approval of Yescarta (axicabtagene ciloleucel), for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Download PDF
